Kailos Genetics recently announced the release of PGxComplete, a comprehensive, full panel, gene-based test, which will be offered at $99 through Nov. 30.
The test traditionally sells for hundreds or thousands of dollars. By reducing the cost of the panel test, Kailos is able to give consumers better access to affordable genetic testing.
“It’s our goal to give people the ability to understand how medicine will work for them before it is prescribed,” Troy Moore, chief scientific officer of Kailos Genetics, said. “With full panel testing, people are able to see how they respond to a variety of medications catered to their lifestyle and needs. Whether someone is preparing for surgery, recovering from a heart attack or managing their cancer treatment, we want them to have the information necessary to make informed treatment decisions.”
The full panel tests 20 different classes of medications to uncover how the body responds to more than 50 types of medications, including antidepressants, opioids, HIV/AIDS treatment and cancer therapy.
PGxComplete enables people to work with their physician to select the right medication and dosage combination based on their DNA. The PGxComplete test was developed using advanced technology that harnesses DNA sequencing and facilitates a more complete view of a person’s gene-based information.